[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.v71.3
|
[2] |
RUGO H S, RUMBLE R B, MACRAE E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline[J]. J Clin Oncol, 2016, 34(25): 3069-3103.
doi: 10.1200/JCO.2016.67.1487
pmid: 27217461
|
[3] |
CARDOSO F, PALUCH-SHIMON S, SENKUS E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)[J]. Ann Oncol, 2020, 31(12): 1623-1649.
doi: 10.1016/j.annonc.2020.09.010
|
[4] |
JI L, CHENG L, ZHU X, et al. Risk and prognostic factors of breast cancer with liver metastases[J]. BMC Cancer, 2021, 21(1): 238.
doi: 10.1186/s12885-021-07968-5
pmid: 33676449
|
[5] |
MA R, FENG Y L, LIN S, et al. Mechanisms involved in breast cancer liver metastasis[J]. J Transl Med, 2015, 13: 64.
doi: 10.1186/s12967-015-0425-0
pmid: 25885919
|
[6] |
SCHRIJVER W A M E, SUIJKERBUIJK K P M, VAN GILS C H, et al. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis[J]. J Natl Cancer Inst, 2018, 110(6): 568-580.
doi: 10.1093/jnci/djx273
pmid: 29315431
|
[7] |
AURILIO G, DISALVATORE D, PRUNERI G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases[J]. Eur J Cancer, 2014, 50(2): 277-289.
doi: 10.1016/j.ejca.2013.10.004
pmid: 24269135
|
[8] |
MODI S N, JACOT W, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
doi: 10.1056/NEJMoa2203690
|
[9] |
DENKERT C, SEITHER F, SCHNEEWEISS A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials[J]. Lancet Oncol, 2021, 22(8): 1151-1161.
doi: 10.1016/S1470-2045(21)00301-6
pmid: 34252375
|
[10] |
TARANTINO P, CURIGLIANO G, TOLANEY S M. Navigating the HER2-low paradigm in breast oncology: new standards, future horizons[J]. Cancer Discov, 2022, 12(9): 2026-2030.
doi: 10.1158/2159-8290.CD-22-0703
|
[11] |
WOLFF A C, SOMERFIELD M R, DOWSETT M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update[J]. J Clin Oncol, 2023, 41(22): 3867-3872.
doi: 10.1200/JCO.22.02864
|
[12] |
ALLISON K H, HAMMOND M E H, DOWSETT M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update[J]. J Clin Oncol, 2020, 38(12): 1346-1366.
doi: 10.1200/JCO.19.02309
pmid: 31928404
|
[13] |
LIU J Q, DENG H R, JIA W J, et al. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment[J]. J Cancer Res Clin Oncol, 2012, 138(5): 837-842.
doi: 10.1007/s00432-012-1150-1
pmid: 22290394
|
[14] |
CURIGLIANO G, BAGNARDI V, VIALE G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice?[J]. Ann Oncol, 2011, 22(10): 2227-2233.
doi: 10.1093/annonc/mdq751
pmid: 21343379
|
[15] |
HOEFNAGEL L D, MOELANS C B, MEIJER S L, et al. Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases[J]. Cancer, 2012, 118(20): 4929-4935.
doi: 10.1002/cncr.27518
pmid: 22415862
|
[16] |
LIEDTKE C, BROGLIO K, MOULDER S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer[J]. Ann Oncol, 2009, 20(12): 1953-1958.
doi: 10.1093/annonc/mdp263
pmid: 19596702
|
[17] |
DIECI M V, BARBIERI E, PIACENTINI F, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis[J]. Ann Oncol, 2013, 24(1): 101-108.
doi: 10.1093/annonc/mds248
pmid: 23002281
|
[18] |
LIN M X, JIN Y Z, LV H, et al. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases[J]. Int J Cancer, 2023, 152(7): 1476-1489.
doi: 10.1002/ijc.v152.7
|
[19] |
LU Y J, TONG Y W, CHEN X S, et al. Association of biomarker discrepancy and treatment decision, disease outcome in recurrent/metastatic breast cancer patients[J]. Front Oncol, 2021, 11: 638619.
doi: 10.3389/fonc.2021.638619
|
[20] |
CURTIT E, NERICH V, MANSI L, et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis[J]. Oncologist, 2013, 18(6): 667-674.
doi: 10.1634/theoncologist.2012-0350
pmid: 23723333
|
[21] |
DUCHNOWSKA R, DZIADZIUSZKO R, TROJANOWSKI T, et al. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain[J]. Breast Cancer Res, 2012, 14(4): R119.
doi: 10.1186/bcr3244
|
[22] |
MCGRANAHAN N, SWANTON C. Clonal heterogeneity and tumor evolution: past, present, and the future[J]. Cell, 2017, 168(4): 613-628.
doi: S0092-8674(17)30066-1
pmid: 28187284
|
[23] |
HU Z, SUN R, CURTIS C. A population genetics perspective on the determinants of intra-tumor heterogeneity[J]. Biochim Biophys Acta Rev Cancer, 2017, 1867(2): 109-126.
doi: 10.1016/j.bbcan.2017.03.001
|
[24] |
NAVIN N, KENDALL J, TROGE J, et al. Tumour evolution inferred by single-cell sequencing[J]. Nature, 2011, 472(7341): 90-94.
doi: 10.1038/nature09807
|
[25] |
MITTENDORF E A, WU Y, SCALTRITI M, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes[J]. Clin Cancer Res, 2009, 15(23): 7381-7388.
doi: 10.1158/1078-0432.CCR-09-1735
pmid: 19920100
|
[26] |
HU Z, LI Z, MA Z C, et al. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases[J]. Nat Genet, 2020, 52(7): 701-708.
doi: 10.1038/s41588-020-0628-z
pmid: 32424352
|
[27] |
MAYNADIER M, NIRDÉ P, RAMIREZ J M, et al. Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells[J]. Adv Exp Med Biol, 2008, 617: 485-491.
doi: 10.1007/978-0-387-69080-3_48
pmid: 18497073
|